The molecule worked unlike Pfizer’s antiviral treatment Paxlovid, which, they said, was only useful during the first three days of showing symptoms.

Molecule Neutralising SARS-CoV-2 Virus Found, Could Reduce Infection Duration Upon Exposure

The study further showed that Nirmatrelvir – sold under Paxlovid -- was associated with reduced risk of Post-Covid-Condition in people who were unvaccinated, vaccinated, and boosted, and in people with primary SARS-CoV-2 infection and reinfection

Pfizer’s New Oral Anti-Viral Drug Lowers Risk of Post-Covid Condition, Study Shows

China, whose home-grown vaccines are seen as less effective than the Moderna and Pfizer-BioNTech mRNA shots, has been racing to develop vaccines using messenger RNA (mRNA) technology since early 2020. The long-awaited approval comes as infections have fallen sharply across China since it suddenly dr…

China okays its first mRNA vaccine, from drugmaker CSPC

Max Financial, Mphasis, Emami, HDFC AMC, Pfizer, Network18, Godrej Agrovet, Laurus Labs and Motilal Oswal Financial were among 34 stocks from the S&P BSE 500 index hit their respective 52-week lows.

Reliance, Wipro, Jubilant FoodWorks, Crompton Greaves hit 52-week lows

Given the muted response to the deal on Monday, analysts seem skeptical that this will be as easy as Pfizer makes it sound

Seagen acquisition: Pfizer can now bet on future of cancer drugs

International Business News: Pfizer has agreed to buy biotech firm Seagen for $43 billion. Seagen is a leading player in the research, development and commercialization of cancer

Pfizer: Pfizer buys biotech firm Seagen for $43 billion - Times of India

Pfizer to Acquire Seagen For $43 bn To Deepen Reach into Treating Cancer

“Together, Pfizer and Seagen seek to accelerate the next generation of cancer breakthroughs and bring new solutions to patients by combining the power of Seagen’s antibody-drug conjugate (ADC) technology with the scale and strength of Pfizer’s capabilities and expertise,” Pfizer Chairman and CEO Dr.…

Pfizer will spend $43 billion to acquire Seagen

Pfizer agrees to buy Seagen for $43 billion

The deal announced Monday will combine Seagen’s technology with Pfizer’s scale and strength, Pfizer CEO Albert Bourla said in a statement. Pfizer’s oncology division brought in $12 billion in revenue last year and already includes treatments for prostate cancer and the breast cancer treatment Ibranc…

Pfizer buys Seagen for $43B, boosts access to cancer drugs

Washington-based Seagen is a pioneer of antibody-drug conjugates, which work like “guided missiles” designed for a targeted destructive effect and spare healthy cells.

Pfizer looks past Covid with $43-bn deal for cancer drug innovator Seagen

Price return has been average, nothing exciting

Performance

Seems to be overvalued vs the market average

Valuation

Financials growth has been moderate for a few years

Growth

Showing good signs of profitability & efficiency

Profitability

The stock is overpriced but is not in the overbought zone

Current price is more than the intrinsic value

Fundamentals

Good time to consider, stock is not in the overbought zone

Technicals

Entry point

Promoter pledged holding

Unsolicited messages

Default probability

Red flags

Pfizer Limited is a pharmaceutical company. The Company has a portfolio of approximately 140 products across over 15 therapeutic areas.

Pfizer Ltd